GTCR is taking a majority stake in PathGroup, at what sources tell Sarah is a $1.2 billion valuation. Ex-Labcorp CEO Dave King will join the national laboratory company as chairman.
Why it matters: Nashville's PathGroup is one of few lab players of scale that remains independent, and this deal opens up new consolidation opportunities. Such assets are considered a friendly partner to providers that don't want to work with industry giants LabCorp and Quest Diagnostics.
